|
|
Other links at Articles > Cardiology |
| 2. |
PFO/ASD-Closure Procedures Increased More Than 50-Fold Between 1998 and 2004
|
|
|
Researchers who tracked closure procedures by ICD-9 code say the increase likely reflects PFO procedures, either off label or under humanitarian device exemption before this was revoked in 2006. Despite no solid proof that closing a PFO prevents stroke, many physicians see minimal risk and potential for major benefits. Heartwire
|
| 3. |
Aliskiren Reduces LVH to Same Extent as Losartan
|
|
|
A combination of the new direct renin inhibitor aliskiren and losartan is no more effective than either drug alone in reducing left ventricular hypertrophy. Nevertheless, the results show that the two drugs are equivalent in this regard, providing the first solid data that aliskiren can reduce LV mass and adding to the body of knowledge about the new drug, says the lead investigator. Heartwire
|
| 4. |
Out of Tune: Rimonabant Fails to Slow Progression of CAD in STRADIVARIUS
|
|
|
The weight loss drug rimonabant has failed to show any benefit on progression of atherosclerosis in an intravascular ultrasound study in patients with abdominal obesity and coronary artery disease. In addition, the drug resulted in higher rates of psychiatric and other side effects compared with placebo. Heartwire
|
| 5. |
Rebound Effect on Stopping Clopidogrel
|
|
|
An increase in cardiac events after stopping clopidogrel in acute coronary syndrome has led to suggestions that the dose may need to be tapered or the drug to be taken for longer periods. Medscape Medical News
|
|
|
